Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13757916 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8140808 | 0.91 | CYP3A4 (0.39) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3809694 | 0.91 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13757917 | 0.91 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL3809700 | 0.91 | ADRB3 (0.49) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8142742 | 0.89 | CYP3A4 (0.40) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13248824 | 0.85 | ADRB3 (0.55) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL8282256 | 0.82 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13248842 | 0.82 | ADRB3 (0.50) | ADRB3ADRA2BADRA2CCYP3A4 | |
| SCHEMBL13248826 | 0.82 | ADRB3 (0.58) | ADRB3ADRA2BADRA2CCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8513186-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2162432-A2 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090186869-A1 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009005677-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186869-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | ADRB3 4323/4885ADRA2B 4738/4885ADRA2C 4546/4885 |
| US-20140051626-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | ADRB3 4323/4885ADRA2B 4738/4885ADRA2C 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.